Skip to main content
Fig. 1 | Gynecologic Oncology Research and Practice

Fig. 1

From: A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib

Fig. 1

Detection of a somatic KRAS mutation (c.35G > T; p.G12V) in DNA extracted from micro-dissected tumor cells from the patient with recurrent low-grade serous carcinoma. DNA extracted from micro-dissected adjacent stromal cells was used as normal control. Sequencing chromatograms were generated using PCR Sanger sequencing with AB3730XL sequencer

Back to article page

Gynecologic Oncology Research and Practice

ISSN: 2053-6844

Contact us